Chemotherapeutic Agents in Brain/Breast
Completed
Conditions studied: Breast Cancer, Metastatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Studying samples of tumor tissue and blood from patients may help doctors understand how well these drugs can be carried to the brain. PURPOSE: More definitive knowledge of the penetration of chemotherapeutic and other agents into the brain is necessary for the future rational design of drug and drug regimens that target brain metastases. This clinical trial is studying how well capecitabine, cyclophosphamide, doxorubicin, gemcitabine, lapatinib, paclitaxel, trastuzumab, or vinorelbine penetrates brain tumors.
Key facts
- Study ID
- NCT00795678
- Run by
- Case Comprehensive Cancer Center
- People needed
- 10
- Starts
- 2008-09-01
- Expected to finish
- 2013-04-01
- Last updated by the study team
- 2013-08-02
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan Kettering — New York, New York, United States
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.